Long-term Outcomes of a Clinical Ketamine Service for Treatment-resistant Depression


About this study

The purpose of this study is to evaluate and analyze the clinical data that is already being collected for clinical purposes to determine the long-term effects of the repeated use of subanaesthetic ketamine/esketamine for patients with depression.  We hypothesize that patients who have a greater number of infusions/treatments will be more likely to have increased side effects to the drug.  We would like to be able to also analyze data related to any other assessments that are implemented as part of the clinical practice in the future.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • All adult  (≥ 18 years) patients.
  • Diagned with Treatment Resistant Depression (TRD) who received/will receive ketamine/esketamine for TRD at Mayo Clinic in Rochester.
  • Willing and able to provide research authorization.

Exclusion Criteria:

  • Patients who declined the opportunity to provide research authorization.



Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Balwinder Singh, M.D.

Closed-enrolling by invitation

What is this? (?)
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Barbara Hall L.S.W.

(507) 266-5374


More information


Publications are currently not available